Diligence memo · auto-generated · as of July 2, 2026

Precision Biosciences Inc

Precision Biosciences Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Precision Biosciences Inc operates in Biotechnology, based in DURHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Precision Biosciences Inc has raised $153M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $88M on 2018-05-25.

Most recent recorded round closed around 2019-03-01.

Valuation (modeled)modeled

Provath models Precision Biosciences Inc at approximately $1.6B (range $122M–$4.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.83× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Within the normal band (83% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 23 months.

Last raise 7.3 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 95% of Biotechnology peers (4293 compared).

Modeled value ranks above 93% of those peers.

Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.